JP2021533726A5 - - Google Patents
Info
- Publication number
- JP2021533726A5 JP2021533726A5 JP2020547399A JP2020547399A JP2021533726A5 JP 2021533726 A5 JP2021533726 A5 JP 2021533726A5 JP 2020547399 A JP2020547399 A JP 2020547399A JP 2020547399 A JP2020547399 A JP 2020547399A JP 2021533726 A5 JP2021533726 A5 JP 2021533726A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acd25
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642232P | 2018-03-13 | 2018-03-13 | |
| US201862642218P | 2018-03-13 | 2018-03-13 | |
| US201862642248P | 2018-03-13 | 2018-03-13 | |
| US201862642243P | 2018-03-13 | 2018-03-13 | |
| US201862642230P | 2018-03-13 | 2018-03-13 | |
| US62/642248 | 2018-03-13 | ||
| US62/642230 | 2018-03-13 | ||
| US62/642232 | 2018-03-13 | ||
| GBGB1804027.9A GB201804027D0 (en) | 2018-03-13 | 2018-03-13 | Anti-CD25 antibody agents |
| GBGB1804029.5A GB201804029D0 (en) | 2018-03-13 | 2018-03-13 | Anti-CD25 antibody agents |
| GBGB1804028.7A GB201804028D0 (en) | 2018-03-13 | 2018-03-13 | Anti-CD25 antibody agents |
| GB1804028.7 | 2018-03-13 | ||
| EPPCT/EP2018/056312 | 2018-03-13 | ||
| GB1804027.9 | 2018-03-13 | ||
| US62/642218 | 2018-03-13 | ||
| US62/642243 | 2018-03-13 | ||
| GB1804029.5 | 2018-03-13 | ||
| PCT/EP2018/056312 WO2018167104A1 (en) | 2017-03-17 | 2018-03-13 | Fc-optimized anti-cd25 for tumour specific cell depletion |
| PCT/EP2019/056249 WO2019175217A1 (en) | 2018-03-13 | 2019-03-13 | Anti-cd25 for tumour specific cell depletion |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533726A JP2021533726A (ja) | 2021-12-09 |
| JP2021533726A5 true JP2021533726A5 (enExample) | 2022-03-18 |
| JP7451415B2 JP7451415B2 (ja) | 2024-03-18 |
Family
ID=67903878
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547371A Active JP7474701B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５抗体 |
| JP2020547331A Active JP7563979B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547332A Active JP7565797B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547415A Pending JP2021515568A (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547363A Active JP7451414B2 (ja) | 2018-03-13 | 2019-03-13 | 抗ｃｄ２５抗体剤 |
| JP2020547333A Active JP7510348B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547326A Active JP7563978B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547399A Active JP7451415B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
Family Applications Before (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020547371A Active JP7474701B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５抗体 |
| JP2020547331A Active JP7563979B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547332A Active JP7565797B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547415A Pending JP2021515568A (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547363A Active JP7451414B2 (ja) | 2018-03-13 | 2019-03-13 | 抗ｃｄ２５抗体剤 |
| JP2020547333A Active JP7510348B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
| JP2020547326A Active JP7563978B2 (ja) | 2018-03-13 | 2019-03-13 | 腫瘍特異的細胞枯渇のための抗ｃｄ２５ |
Country Status (14)
| Country | Link |
|---|---|
| US (11) | US10745485B2 (enExample) |
| EP (8) | EP3765502B1 (enExample) |
| JP (8) | JP7474701B2 (enExample) |
| KR (3) | KR20200131286A (enExample) |
| CN (8) | CN112020516B (enExample) |
| AU (3) | AU2019233576A1 (enExample) |
| BR (3) | BR112020016519A2 (enExample) |
| CA (3) | CA3088246A1 (enExample) |
| CR (3) | CR20200467A (enExample) |
| MA (1) | MA51993A (enExample) |
| PE (3) | PE20210288A1 (enExample) |
| SG (3) | SG11202008733YA (enExample) |
| TW (3) | TW202003034A (enExample) |
| WO (8) | WO2019175226A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11371066B2 (en) | 2015-07-13 | 2022-06-28 | Modular Genetics, Inc. | Generation of acyl alcohols |
| PL3440109T3 (pl) * | 2016-04-07 | 2025-12-01 | Cancer Research Technology Limited | Przeciwciała przeciwko receptorowi gamma CD25 fc do zmniejszenia liczebności komórek swoistych dla nowotworu w skojarzeniu z antagonistami PD-1 |
| CN108795858A (zh) * | 2017-04-28 | 2018-11-13 | 深圳宾德生物技术有限公司 | 高抗癌活性t细胞的筛选方法和应用 |
| CN112020516B (zh) | 2018-03-13 | 2025-01-03 | 塔斯克疗法有限公司 | 用于肿瘤特异性细胞清除的抗-cd25 |
| CN114630838A (zh) * | 2019-05-20 | 2022-06-14 | 法国国家健康和医学研究院 | 新的抗cd25抗体 |
| TWI877278B (zh) | 2019-12-30 | 2025-03-21 | 美商思進公司 | 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法 |
| TW202144429A (zh) | 2020-05-14 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｃｄ２５抗體、其抗原結合片段及其醫藥用途 |
| US11124568B1 (en) * | 2020-08-19 | 2021-09-21 | Vitruviae LLC | CD3/CD25 antibodies for neuro-immune diseases |
| JP7621481B2 (ja) * | 2020-11-13 | 2025-01-24 | アイバイオ， インク． | Ｃｄ２５抗体 |
| US20240002521A1 (en) * | 2020-11-20 | 2024-01-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd25 antibodies |
| US20240002522A1 (en) * | 2020-11-20 | 2024-01-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Anti-cd25 antibodies |
| JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト |
| WO2022182483A1 (en) | 2021-02-02 | 2022-09-01 | Rakuten Medical, Inc. | Methods for local and systemic treatment of cancers, tumors and tumor cells |
| JP2024507972A (ja) * | 2021-03-01 | 2024-02-21 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 新規バイオマーカーおよびその使用 |
| CN115724971A (zh) | 2021-08-09 | 2023-03-03 | 南京诺艾新生物技术有限公司 | 重组抗人cd25抗体及其应用 |
| JP2024534053A (ja) * | 2021-08-25 | 2024-09-18 | アイバイオ， インク． | 抗ｃｄ２５抗体 |
| WO2023031403A1 (en) | 2021-09-02 | 2023-03-09 | F. Hoffmann-La Roche Ag | Antibodies for the treatment of aml |
| CA3230426A1 (en) * | 2021-09-03 | 2023-03-09 | Novarock Biotherapeutics, Ltd. | Bispecific binding proteins that bind cd137 and a tumor associated antigen |
| US20250154268A1 (en) * | 2022-01-17 | 2025-05-15 | Nona Biosciences (Suzhou) Co., Ltd. | Antibody targeting cd25, and preparation method therefor and use thereof |
| JP2025514847A (ja) | 2022-04-26 | 2025-05-09 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｆａｓ軸拮抗薬及びＴｒｅｇ細胞枯渇剤拮抗薬を含む癌の治療のための併用療法 |
| CN115197321B (zh) * | 2022-06-02 | 2023-08-18 | 四川大学 | 靶向cd25的抗体及其用途 |
| CN115181181B (zh) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | 一种抗cd25的单域抗体及其应用 |
| CN115181182B (zh) * | 2022-06-13 | 2024-03-29 | 南京融捷康生物科技有限公司 | 一种人源化的抗cd25的单域抗体及其应用 |
| JP2025525451A (ja) * | 2022-06-30 | 2025-08-05 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｃｄ２５特異的抗体およびその使用 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| CN118240080A (zh) * | 2022-12-22 | 2024-06-25 | 深圳市福元生物科技有限公司 | 一种cd25单域抗体、人源化抗体、及制备方法 |
| CN116004636B (zh) * | 2023-01-10 | 2024-03-12 | 广西师范大学 | 一种不结合红细胞的差异化cd47核酸适体及其应用 |
| CN120584138A (zh) | 2023-02-06 | 2025-09-02 | 豪夫迈·罗氏有限公司 | 组合疗法及其用途 |
| TW202444757A (zh) * | 2023-03-14 | 2024-11-16 | 美商奧迪希治療公司 | 抗cd25抗原結合蛋白及其用途 |
| KR20250164708A (ko) * | 2023-03-29 | 2025-11-25 | 다이이찌 산쿄 가부시키가이샤 | 항 cd25 항체 및 항 cd25 항체-약물 콘주게이트 |
| TW202509067A (zh) * | 2023-04-11 | 2025-03-01 | 大陸商蘇州創勝醫藥集團有限公司 | 抗ｃｄ２５抗體及其用途 |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| CN122459678A (zh) | 2023-12-29 | 2026-07-24 | 百时美施贵宝公司 | KRAS抑制剂与Treg耗竭剂的组合疗法 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2026006708A2 (en) * | 2024-06-27 | 2026-01-02 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
| WO2026002198A1 (zh) * | 2024-06-28 | 2026-01-02 | 百奥泰生物制药股份有限公司 | 抗cd25抗体及其应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4208479A (en) | 1977-07-14 | 1980-06-17 | Syva Company | Label modified immunoassays |
| US4578335A (en) * | 1984-05-21 | 1986-03-25 | Immunex Corporation | Interleukin 2 receptor |
| AU2003295471B2 (en) | 2002-11-15 | 2011-08-25 | Genmab A/S | Human monoclonal antibodies against CD25 |
| US20050181375A1 (en) | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
| US8795672B2 (en) | 2003-02-14 | 2014-08-05 | University Of Southern California | Compositions and methods for cancer immunotherapy |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| CN101072578A (zh) | 2004-10-29 | 2007-11-14 | 南加州大学 | 用共刺激分子的联合癌症免疫疗法 |
| GB0507696D0 (en) | 2005-04-15 | 2005-05-25 | Novartis Ag | Organic compounds |
| JP2009542592A (ja) | 2006-07-06 | 2009-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法 |
| CA2661023C (en) | 2006-08-18 | 2017-08-15 | Novartis Ag | Prlr-specific antibody and uses thereof |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| RU2391401C2 (ru) | 2008-02-12 | 2010-06-10 | Общество с ограниченной ответственностью "Лаборатория клеточного мониторинга" | СПОСОБ ПОЛУЧЕНИЯ ПОПУЛЯЦИИ CD4+CD25+Foxp3+ Т-ЛИМФОЦИТОВ ЧЕЛОВЕКА ex vivo, СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
| US9221902B2 (en) | 2008-11-07 | 2015-12-29 | Fabrus, Inc. | Combinatorial antibody libraries and uses thereof |
| KR101545914B1 (ko) * | 2009-09-22 | 2015-08-20 | 프로바이오겐 아게 | 특수화된 글리칸 구조를 함유하는 분자의 생산 방법 |
| WO2011077245A2 (en) | 2009-12-23 | 2011-06-30 | Fondazione Centro San Raffaele Del Monte Tabor | Compositions |
| TWI513466B (zh) | 2010-01-20 | 2015-12-21 | Boehringer Ingelheim Int | 抗凝血劑解毒劑 |
| EP2378287A1 (en) * | 2010-04-15 | 2011-10-19 | TXCell | New method for isolating Tr1 cells |
| KR20130048242A (ko) | 2010-07-22 | 2013-05-09 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 항-종양 항원 항체 및 이용 방법 |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| AU2014233478A1 (en) * | 2013-03-15 | 2015-09-24 | Abbvie Biotechnology Ltd. | Anti-CD25 antibodies and their uses |
| EP2970489A2 (en) | 2013-03-15 | 2016-01-20 | AbbVie Biotechnology Ltd | Anti-cd25 antibodies and their uses |
| EP3421495A3 (en) * | 2013-03-15 | 2019-05-15 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| EP3003390B1 (en) * | 2013-06-06 | 2021-07-07 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
| WO2015109212A1 (en) * | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| GB201403775D0 (en) * | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| MX2016017288A (es) | 2014-07-16 | 2017-06-27 | Genentech Inc | Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer. |
| KR102524920B1 (ko) * | 2014-07-22 | 2023-04-25 | 아폴로믹스 인코포레이티드 | 항-pd-1 항체 |
| US11219672B2 (en) | 2014-08-07 | 2022-01-11 | Haruki Okamura | Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody |
| US11147652B2 (en) | 2014-11-13 | 2021-10-19 | Align Technology, Inc. | Method for tracking, predicting, and proactively correcting malocclusion and related issues |
| SG11201704056XA (en) * | 2014-11-20 | 2017-06-29 | Hoffmann La Roche | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
| JP6805142B2 (ja) * | 2014-11-21 | 2020-12-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｄ７３に対する抗体およびその使用 |
| AR103268A1 (es) * | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| IL254039B2 (en) | 2015-02-19 | 2023-12-01 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
| JP6815329B2 (ja) * | 2015-03-23 | 2021-01-20 | バイエル ファーマ アクチエンゲゼルシャフト | 抗ｃｅａｃａｍ６抗体およびその使用 |
| EP3365369A1 (en) * | 2015-10-23 | 2018-08-29 | Pfizer Inc | Anti-il-2 antibodies and compositions and uses thereof |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| AU2017228470A1 (en) * | 2016-03-04 | 2018-08-30 | Bristol-Myers Squibb Company | Combination therapy with anti-CD73 antibodies |
| RU2693661C2 (ru) * | 2016-03-04 | 2019-07-03 | Сычуань Келунь-Байотек Байофармасьютикал Ко., Лтд. | Антитело против pdl-1, его фармацевтическая композиция и применение |
| PL3440109T3 (pl) | 2016-04-07 | 2025-12-01 | Cancer Research Technology Limited | Przeciwciała przeciwko receptorowi gamma CD25 fc do zmniejszenia liczebności komórek swoistych dla nowotworu w skojarzeniu z antagonistami PD-1 |
| CA3027121A1 (en) * | 2016-06-10 | 2017-12-14 | Regeneron Pharmaceuticals, Inc. | Anti-gitr antibodies and uses thereof |
| JP6831651B2 (ja) | 2016-07-04 | 2021-02-17 | 川崎重工業株式会社 | ワークの袋詰め装置 |
| EP3538548A4 (en) | 2016-11-08 | 2020-08-19 | Delinia, Inc. | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| US11119165B2 (en) | 2017-06-28 | 2021-09-14 | North Carolina State University Office of Research Commercialization | Photonic band-gap resonator for magnetic resonance applications |
| WO2019008386A1 (en) | 2017-07-06 | 2019-01-10 | Tusk Therapeutics Ltd | COMPOUNDS AND METHODS FOR DEPLOYING SPECIFIC CELLS FROM A TUMOR |
| MX2020008768A (es) | 2018-03-13 | 2020-10-08 | Tusk Therapeutics Ltd | Agentes anticuerpos anti-cd25. |
| CN112020516B (zh) | 2018-03-13 | 2025-01-03 | 塔斯克疗法有限公司 | 用于肿瘤特异性细胞清除的抗-cd25 |
| KR20200003558A (ko) | 2018-07-02 | 2020-01-10 | 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. | 용지 슬립을 방지하기 위한 급지장치 및 이를 포함하는 화상형성장치 |
| KR102080909B1 (ko) | 2018-07-06 | 2020-02-24 | 한국수력원자력 주식회사 | 원자로의 해체 시스템 |
-
2019
- 2019-03-13 CN CN201980019256.8A patent/CN112020516B/zh active Active
- 2019-03-13 BR BR112020016519-0A patent/BR112020016519A2/pt not_active Application Discontinuation
- 2019-03-13 BR BR112020016499-2A patent/BR112020016499A2/pt not_active Application Discontinuation
- 2019-03-13 US US16/352,717 patent/US10745485B2/en active Active
- 2019-03-13 SG SG11202008733YA patent/SG11202008733YA/en unknown
- 2019-03-13 TW TW108108467A patent/TW202003034A/zh unknown
- 2019-03-13 US US16/352,709 patent/US10752691B2/en active Active
- 2019-03-13 CN CN201980019241.1A patent/CN112020512B/zh active Active
- 2019-03-13 US US16/352,703 patent/US10738125B2/en active Active
- 2019-03-13 PE PE2020001299A patent/PE20210288A1/es unknown
- 2019-03-13 WO PCT/EP2019/056260 patent/WO2019175226A1/en not_active Ceased
- 2019-03-13 PE PE2020001292A patent/PE20210287A1/es unknown
- 2019-03-13 JP JP2020547371A patent/JP7474701B2/ja active Active
- 2019-03-13 EP EP19709954.2A patent/EP3765502B1/en active Active
- 2019-03-13 WO PCT/EP2019/056247 patent/WO2019175215A1/en not_active Ceased
- 2019-03-13 EP EP19709958.3A patent/EP3765506B1/en active Active
- 2019-03-13 EP EP19711315.2A patent/EP3765511B1/en active Active
- 2019-03-13 CN CN201980019235.6A patent/CN112041345B/zh active Active
- 2019-03-13 WO PCT/EP2019/056249 patent/WO2019175217A1/en not_active Ceased
- 2019-03-13 KR KR1020207029205A patent/KR20200131286A/ko not_active Withdrawn
- 2019-03-13 PE PE2020001320A patent/PE20210289A1/es unknown
- 2019-03-13 US US16/979,932 patent/US11873341B2/en active Active
- 2019-03-13 US US16/979,935 patent/US11697688B2/en active Active
- 2019-03-13 CN CN201980019247.9A patent/CN112020513B/zh active Active
- 2019-03-13 WO PCT/EP2019/056252 patent/WO2019175220A1/en not_active Ceased
- 2019-03-13 CN CN201980019248.3A patent/CN112020514B/zh active Active
- 2019-03-13 AU AU2019233576A patent/AU2019233576A1/en not_active Abandoned
- 2019-03-13 WO PCT/EP2019/056258 patent/WO2019175224A1/en not_active Ceased
- 2019-03-13 KR KR1020207029221A patent/KR102909650B1/ko active Active
- 2019-03-13 CN CN201980019257.2A patent/CN112218891B/zh active Active
- 2019-03-13 EP EP19709957.5A patent/EP3765505B1/en active Active
- 2019-03-13 EP EP19711075.2A patent/EP3765510A1/en active Pending
- 2019-03-13 CA CA3088246A patent/CA3088246A1/en not_active Abandoned
- 2019-03-13 JP JP2020547331A patent/JP7563979B2/ja active Active
- 2019-03-13 JP JP2020547332A patent/JP7565797B2/ja active Active
- 2019-03-13 CR CR20200467A patent/CR20200467A/es unknown
- 2019-03-13 EP EP19709956.7A patent/EP3765504B1/en active Active
- 2019-03-13 US US16/979,931 patent/US11851494B2/en active Active
- 2019-03-13 KR KR1020207029229A patent/KR20200131862A/ko not_active Withdrawn
- 2019-03-13 CR CR20200465A patent/CR20200465A/es unknown
- 2019-03-13 EP EP19709955.9A patent/EP3765503B1/en active Active
- 2019-03-13 AU AU2019233581A patent/AU2019233581B2/en active Active
- 2019-03-13 SG SG11202008699WA patent/SG11202008699WA/en unknown
- 2019-03-13 AU AU2019233575A patent/AU2019233575A1/en not_active Abandoned
- 2019-03-13 EP EP19710416.9A patent/EP3765507B1/en active Active
- 2019-03-13 TW TW108108451A patent/TW201938588A/zh unknown
- 2019-03-13 BR BR112020016501-8A patent/BR112020016501A2/pt unknown
- 2019-03-13 MA MA051993A patent/MA51993A/fr unknown
- 2019-03-13 US US16/979,929 patent/US11802161B2/en active Active
- 2019-03-13 CN CN201980019234.1A patent/CN112074536B/zh active Active
- 2019-03-13 JP JP2020547415A patent/JP2021515568A/ja active Pending
- 2019-03-13 CN CN201980019249.8A patent/CN112020515B/zh active Active
- 2019-03-13 JP JP2020547363A patent/JP7451414B2/ja active Active
- 2019-03-13 TW TW108108452A patent/TW201940515A/zh unknown
- 2019-03-13 CA CA3088671A patent/CA3088671A1/en active Pending
- 2019-03-13 JP JP2020547333A patent/JP7510348B2/ja active Active
- 2019-03-13 WO PCT/EP2019/056256 patent/WO2019175222A1/en not_active Ceased
- 2019-03-13 CR CR20200466A patent/CR20200466A/es unknown
- 2019-03-13 JP JP2020547326A patent/JP7563978B2/ja active Active
- 2019-03-13 WO PCT/EP2019/056257 patent/WO2019175223A1/en not_active Ceased
- 2019-03-13 WO PCT/EP2019/056248 patent/WO2019175216A1/en not_active Ceased
- 2019-03-13 SG SG11202008784RA patent/SG11202008784RA/en unknown
- 2019-03-13 US US16/979,933 patent/US11919960B2/en active Active
- 2019-03-13 US US16/979,930 patent/US11814434B2/en active Active
- 2019-03-13 JP JP2020547399A patent/JP7451415B2/ja active Active
- 2019-03-13 CA CA3088659A patent/CA3088659A1/en not_active Abandoned
-
2020
- 2020-02-05 US US16/782,440 patent/US11802160B2/en active Active
- 2020-02-05 US US16/782,461 patent/US11787866B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021515565A5 (enExample) | ||
| JP2021516974A5 (enExample) | ||
| JP2021516973A5 (enExample) | ||
| JP2021515568A5 (enExample) | ||
| JP2021516975A5 (enExample) | ||
| JP2021516976A5 (enExample) | ||
| JP2021515566A5 (enExample) | ||
| JP6518005B2 (ja) | Ｐｄ−ｌ１抗体 | |
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| US20210024635A1 (en) | Anti-wt1/hla-specific antibodies | |
| JP2020515247A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| CN110536903A (zh) | 抗ox40抗体及其用途 | |
| JP2018510636A5 (enExample) | ||
| JP2020531043A (ja) | 抗４−１ｂｂ抗体とその作製及び使用方法 | |
| JP2020522280A5 (enExample) | ||
| JP2020522281A5 (enExample) | ||
| JP2020533965A5 (enExample) | ||
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| JP2018508475A (ja) | 抗ｐｄ−ｌ１抗体 | |
| JP2020531003A5 (enExample) | ||
| JP2024540148A5 (enExample) | ||
| CN115812081A (zh) | 抗ctla-4抗体及其用途 | |
| JP2024527576A5 (enExample) | ||
| JP2022502079A5 (enExample) |